Consensus ADC Therapeutics SA

Equities

ADCT

CH0499880968

Market Closed - Nyse Other stock markets 16:00:02 2024-04-26 EDT			5-day change	1st Jan Change
4.34 ^USD	-2.25%		-8.05%	+161.45%

04-09	Transcript : ADC Therapeutics SA - Special Call
04-04	Sector Update: Health Care Stocks Slump Late Afternoon	MT

Evolution of the average Target Price on ADC Therapeutics SA

Price target over the last 5 years

History of analyst recommendation changes

80.4eLME16t25Hmo76p_K4Lvhica60yAUFxlf-79xLIpD4.vqC1QW_p9uKt-ejri8tii3vwXOp3UQUg-6CPzlqB8ni5jPREHf2j2ZXHig~0b092b4f182ffba246d3ece6cfe1bfae

Analyst Recommendations on ADC Therapeutics SA

Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target	03-28	MT
RBC Lifts Price Target on ADC Therapeutics to $8 From $6, 'Encouraged' by Competitive Positioning; Outperform, Speculative Risk Kept	02-26	MT
HC Wainwright Raises Price Target on ADC Therapeutics to $9 From $3, Maintains Buy Rating	02-20	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics to $3 From $12, Keeps Buy Rating	11-20	MT
TD Cowen Downgrades ADC Therapeutics to Market Perform From Outperform	11-09	MT
RBC Cuts Price Target on ADC Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	11-08	MT
RBC Trims Price Target on ADC Therapeutics to $8 From $9 Amid Guidance Withdrawal, Keeps Outperform, Speculative Risk	23-09-12	MT
JPMorgan Upgrades ADC Therapeutics to Neutral From Underweight	23-08-10	MT
RBC Trims Price Target on ADC Therapeutics to $9 From $10, Maintains Outperform Rating, Speculative Risk Qualifier	23-08-09	MT
HC Wainwright Lowers Price Target on ADC Therapeutics to $12 From $20, Maintains Buy Rating	23-06-20	MT
RBC Cuts Price Target on ADC Therapeutics to $10 From $12, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-10	MT
BofA Securities Downgrades ADC Therapeutics to Underperform From Neutral, Adjusts Price Target to $2 From $7	23-04-24	MT
RBC Cuts Price Target on ADC Therapeutics to $12 From $18, Maintains Outperform, Speculative Risk	23-02-13	MT
Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalweight Rating	23-01-24	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $21, Maintains Buy Rating	23-01-04	MT
Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Equal-Weight Rating	22-11-14	MT
BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $14	22-11-09	MT
RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cami Launch; Maintains Outperform, Speculative Risk Rating	22-11-09	MT
RBC Cuts Price Target on ADC Therapeutics to $25 From $29, Maintains Outperform Rating	22-10-06	MT
JPMorgan Starts ADC Therapeutics at Underweight with $5 Price Target	22-09-21	MT
HC Wainwright Adjusts ADC Therapeutics' Price Target to $21 From $20, Maintains Buy Rating	22-09-19	MT
Morgan Stanley Downgrades ADC Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $17	22-09-09	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $44, Reiterates Buy Rating	22-08-22	MT
HC Wainwright Adjusts Price Target on ADC Therapeutics to $44 From $54, Reiterates Buy Rating	22-07-11	MT
Morgan Stanley Lowers ADC Therapeutics SA's Price Target to $17 From $30, Maintains Overweight Rating	22-05-10	MT